Pfizer Inc. CEO Albert Bourla discusses how uncertainty over proposed pharmaceutical tariffs by President Trump is limiting the company's investment in the US, despite reporting an...
Pfizer CEO Albert Bourla highlights how uncertainty over proposed pharmaceutical tariffs by President Trump is limiting the company's investment in the US, despite reporting an 8% ...
Pfizer Inc. announced an 8% revenue decline to $13.7 billion in Q1 2025, with a 5% drop in net income and EPS. CFO David Denton highlights operational efficiency driving financial ...
Pfizer Inc. announced an 8% decrease in Q1 revenue to $13.7 billion for FY2025, with a 5% drop in net income and EPS. CFO David Denton highlights operational efficiency driving res...
Pfizer Inc. announced its Q1 2025 financial results, revealing an 8% annual revenue decrease to $13.7 billion. Despite a 5% drop in net income and EPS, the company's shares rose by...
Pfizer Inc. discontinues development of danuglipron, a weight management pill, after a trial participant experiences liver injury. The company vows to continue research in obesity ...
Pfizer stops the development of its weight loss pill, danuglipron, after a trial participant suffered liver injury. The company vows to continue its research in obesity treatments,...
Pfizer Inc. stops development of weight loss pill danuglipron after a trial participant suffers liver injury. The company pledges to continue research into obesity treatments, high...
Pfizer Inc. has discontinued the development of its weight management pill, danuglipron, after a trial participant experienced liver injury. The company remains focused on advancin...
The US Attorney's office is investigating claims that Pfizer delayed announcing its COVID-19 vaccine success until after the 2020 election. Former employee Phil Dormitzer's alleged...
Pfizer projects its 2025 revenue to reach up to $64 billion, with steady COVID-19 product sales and anticipated operational growth of 10% to 18% year-over-year.
